Related Experiment Videos

Oncogenes in clinical cancer--a panel discussion

W L McGuire¹, B E Johnson, R C Seeger

¹University of Texas Health Science Center, San Antonio.

Breast Cancer Research and Treatment

|December 1, 1987

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025

Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2.

ESMO open·2025

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Lung cancer research and treatment: global perspectives and strategic calls to action.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Breast cancer research : BCR·2023

See all related articles